Infants
are most vulnerable to diseases such as polio, epilepsy,
encephaliphitis, asthma, COPD and other respiratory disease,
diarrhea, leukemia, anemia, and other rare diseases that results in
substantial economic burden.
Newborn
screening describes various tests that are performed during first few
hours or days of an infant’s life. These tests have the potential
of preventing severe health problems and prevents from death.
According to American Academy of Pediatrics: 2018, newborn screening
and diagnosis are important to ensure that all babies who are deaf or
hard of hearing are identified as soon as possible. According to same
source, 1 to 3 out of every 1,000 babies born in the U.S. have
hearing level outside the typical range. When these babies receive
early intervention services, it makes a big difference in their
communication and language development in the future.
Asia
Pacific newborn screening market size was valued at US$ 171.3 million
in 2017 and is expected to witness a CAGR of 12.7% during the
forecast period (2018 – 2026).
Get
PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2546
Increasing
government initiatives is expected to drive growth of the Asia
Pacific newborn screening market
Increasing
engagement programs by various government healthcare regulatory
bodies for newborn screening and its deployment for wider population
base are expected to drive growth of the market during the forecast
period. For instance, in June 2014, PerkinElmer, a company engaged in
the diagnostics, life science research, food, environmental and
industrial testing area, entered into an exclusive collaboration with
China's National Health and Family Planning Commission (NHFPC) to
implement a three-year training program for newborn screening.
The
National Maternal & Children Health Surveillance Office (NMCHSO)
is working with PerkinElmer, to increase availability and adoption of
newborn screening in China, particularly via expansion in more rural
areas.
Asia
Pacific Newborn Screening Market- Country Analysis
On
the basis of country, Asia Pacific newborn screening market is
segmented into China, India, Japan, Australia, South Korea, ASEAN,
and Rest of Asia Pacific. China holds the major share due to
innovative and new initiatives by government for implementing various
newborn screening programs. Currently Congenital Hypothyroidism (CH)
and Phenylketonuria (PKU) and hearing loss are included as national
wide screening program in China, which is also mandatory for all
newborn.
Asia
Pacific Newborn Screening Market- Competitive Landscape
Key
players operating in the Asia Pacific newborn screening market
include Medtronic plc, Agilent Technologies, Waters Technologies
Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life
Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc.,
Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
Detailed
Segmentation:
Asia
Pacific Newborn Screening Market, By Product Type:
-
Hearing Screening Devices
-
Mass Spectrometer
-
Pulse Oximetry
-
Assay Kits and Reagents
Asia
Pacific Newborn Screening Market, By Test Type:
-
Phenylketonuria (PKU)
-
Critical Congenital Heart Defect (CCHD)
-
Hearing Screening
-
Sickle Cell Disease
-
Maple Syrup Urine Disease (MSUD)
-
Thyroid Disorder
-
Biotinidase Deficiency (BTD)
-
Others
Browse
In-Depth Analysis Research Report:
https://www.coherentmarketinsights.com/market-insight/asia-pacific-newborn-screening-market-2546
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment